CR11266A - Derivados de pirrolidin-2ona como moduladores del receptor de androgeno - Google Patents

Derivados de pirrolidin-2ona como moduladores del receptor de androgeno

Info

Publication number
CR11266A
CR11266A CR11266A CR11266A CR11266A CR 11266 A CR11266 A CR 11266A CR 11266 A CR11266 A CR 11266A CR 11266 A CR11266 A CR 11266A CR 11266 A CR11266 A CR 11266A
Authority
CR
Costa Rica
Prior art keywords
2ona
pirrolidin
derivatives
receiver modulators
androgen
Prior art date
Application number
CR11266A
Other languages
English (en)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR11266A publication Critical patent/CR11266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Abstract

Un compuesto representado por la formula (1) de acuerdo con la reinvindicacion I o una sal de el, que tiene una accion moduladora superior del receptor de androgeno.
CR11266A 2007-08-07 2010-02-12 Derivados de pirrolidin-2ona como moduladores del receptor de androgeno CR11266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19

Publications (1)

Publication Number Publication Date
CR11266A true CR11266A (es) 2010-03-22

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11266A CR11266A (es) 2007-08-07 2010-02-12 Derivados de pirrolidin-2ona como moduladores del receptor de androgeno

Country Status (35)

Country Link
US (2) US7834051B2 (es)
EP (1) EP2176220B1 (es)
JP (1) JP5292390B2 (es)
KR (1) KR20100049644A (es)
CN (1) CN101821235B (es)
AR (1) AR067823A1 (es)
AU (1) AU2008284662B2 (es)
BR (1) BRPI0814957B8 (es)
CA (1) CA2695852C (es)
CL (1) CL2008002313A1 (es)
CO (1) CO6160326A2 (es)
CR (1) CR11266A (es)
CY (1) CY1114067T1 (es)
DK (1) DK2176220T3 (es)
DO (1) DOP2010000053A (es)
EA (1) EA017429B1 (es)
ES (1) ES2406685T3 (es)
GE (1) GEP20125571B (es)
HK (1) HK1143972A1 (es)
HR (1) HRP20130374T1 (es)
JO (1) JO2864B1 (es)
MA (1) MA31639B1 (es)
ME (1) ME01579B (es)
MX (1) MX2010001484A (es)
MY (1) MY159910A (es)
NZ (1) NZ583624A (es)
PE (1) PE20090899A1 (es)
PL (1) PL2176220T3 (es)
PT (1) PT2176220E (es)
RS (1) RS52812B (es)
SI (1) SI2176220T1 (es)
TN (1) TN2010000062A1 (es)
TW (1) TWI418543B (es)
WO (1) WO2009020234A2 (es)
ZA (1) ZA201001289B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834051B2 (en) * 2007-08-07 2010-11-16 Takeda Pharmaceutical Company Limited Cyclic amine compounds
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
US8268872B2 (en) * 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US20090270361A1 (en) * 2008-03-26 2009-10-29 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
US20130053448A1 (en) 2010-05-12 2013-02-28 Louis O'Dea Therapeutic Regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2013152170A1 (en) * 2012-04-04 2013-10-10 Catylix, Inc. Selective androgen receptor modulators
EP2950790A4 (en) 2012-08-09 2018-04-25 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
WO2014044357A1 (de) 2012-09-21 2014-03-27 Merck Patent Gmbh Verbindungen mit einer c-c-dreifachbindung und deren verwendung in flüssigkristallmischungen
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
AU754529B2 (en) * 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
CN1617715B (zh) 2001-12-06 2010-05-12 Gtx公司 用雄激素受体选择性调节剂治疗肌消耗
CA2471754A1 (en) 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Androgen receptor antagonist
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
EP1534663A4 (en) 2002-06-17 2006-08-30 Univ Tennessee Res Foundation SELECTIVE MODULATORS OF THE N-BRIDGE ANDROGEN RECEPTOR AND METHODS OF USE
MXPA05001631A (es) 2002-08-12 2005-08-19 Takeda Pharmaceutical Derivado de benceno fusionado y su uso.
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
WO2005090282A1 (en) * 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP1747193A1 (en) * 2004-05-11 2007-01-31 Pfizer Products Incorporated Benzonitrile derivatives to treat musculoskeletal frailty
CA2566942A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
PL2289872T3 (pl) 2004-06-07 2017-12-29 University Of Tennessee Research Foundation Medyczne zastosowania selektywnego modulatora receptora androgenowego
NZ555974A (en) 2005-01-10 2010-11-26 Acadia Pharm Inc Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
MX2007014053A (es) 2005-05-13 2008-02-05 Lilly Co Eli N-arilpirrolidinas substituidas como moduladores selectivos de receptor de androgeno.
US8592452B2 (en) 2005-08-01 2013-11-26 Takeda Pharmaceutical Company Limited Cyclic amine compound
EP1987827A1 (en) 2006-02-20 2008-11-05 Takeda Pharmaceutical Company Limited Novel pharmaceutical
WO2008011072A2 (en) * 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
WO2008014311A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
US8013008B2 (en) 2006-11-30 2011-09-06 Takeda Pharmaceutical Company Limited Cyclic amine compound
US7834051B2 (en) 2007-08-07 2010-11-16 Takeda Pharmaceutical Company Limited Cyclic amine compounds

Also Published As

Publication number Publication date
BRPI0814957A2 (pt) 2015-02-03
AU2008284662B2 (en) 2013-07-25
CY1114067T1 (el) 2016-07-27
JO2864B1 (en) 2015-03-15
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
CA2695852C (en) 2017-01-03
DOP2010000053A (es) 2010-07-15
RS52812B (en) 2013-10-31
EA201070246A1 (ru) 2010-08-30
HRP20130374T1 (en) 2013-05-31
BRPI0814957B1 (pt) 2019-12-03
KR20100049644A (ko) 2010-05-12
US8420694B2 (en) 2013-04-16
US20090042967A1 (en) 2009-02-12
EP2176220A2 (en) 2010-04-21
CO6160326A2 (es) 2010-05-20
CA2695852A1 (en) 2009-02-12
AU2008284662A1 (en) 2009-02-12
BRPI0814957B8 (pt) 2021-05-25
GEP20125571B (en) 2012-07-10
EA017429B1 (ru) 2012-12-28
PE20090899A1 (es) 2009-08-06
DK2176220T3 (da) 2013-06-10
JP2010535704A (ja) 2010-11-25
AR067823A1 (es) 2009-10-21
MX2010001484A (es) 2010-03-04
NZ583624A (en) 2012-06-29
HK1143972A1 (en) 2011-01-21
EP2176220B1 (en) 2013-03-27
MA31639B1 (fr) 2010-08-02
TW200916439A (en) 2009-04-16
ZA201001289B (en) 2011-04-28
WO2009020234A2 (en) 2009-02-12
SI2176220T1 (sl) 2013-05-31
ES2406685T3 (es) 2013-06-07
CL2008002313A1 (es) 2009-05-15
PT2176220E (pt) 2013-04-09
PL2176220T3 (pl) 2013-08-30
JP5292390B2 (ja) 2013-09-18
MY159910A (en) 2017-02-15
US7834051B2 (en) 2010-11-16
TWI418543B (zh) 2013-12-11
TN2010000062A1 (en) 2011-09-26
WO2009020234A3 (en) 2009-04-16
CN101821235A (zh) 2010-09-01
CN101821235B (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
CR11266A (es) Derivados de pirrolidin-2ona como moduladores del receptor de androgeno
UY32469A (es) Composiciones y metodos para modular la senda de señalizacion de wnt
UA107791C2 (en) Pesticidal compositions
CR20110432A (es) Pirimidinas fusionadas
SV2009003349A (es) Compuestos triciclicos, composiciones y procedimientos
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
AU2011232516A8 (en) Chemical compounds
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
BR112017006253A2 (pt) novos compostos
EA201071201A1 (ru) ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71
EA201791359A1 (ru) Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина
TN2011000286A1 (en) Spiroheterocyclic n-oxypiperidines as pesticides
CR20110268A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
UY31688A1 (es) Plaguicidas
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
CR11136A (es) INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC
CR20110474A (es) Derivados de benzofurano
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
IN2012DN02876A (es)
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
CO6491037A2 (es) Derivados de pirazinooxazepina
AR103355A1 (es) Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística
AR103317A1 (es) Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina